There's a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with $68 million in funding that will be used to fund development of a pipeline of ...
ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressive form of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results